Abliva AB

Equities

ABLI

SE0002575340

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:52 2024-05-20 am EDT			5-day change	1st Jan Change
0.193 ^SEK	-2.43%		+0.63%	-21.38%

Feb. 23	Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	CI
2023	Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	CI

NeuroVive Pharmaceutical AB Elects Magnus Persson as New Board Member

April 25, 2019 at 12:30 pm EDT

NeuroVive Pharmaceutical AB elected Magnus Persson as new board member in the annual general meeting held on April 25, 2019.

Latest news about Abliva AB

Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 23	CI
Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study	Dec. 20	CI
EU Commission Grants Orphan Drug Designation to Abliva’s Mitochondrial Disease Drug Candidate; Stock Jumps	Dec. 14	MT
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 17	CI
Abliva AB and Owl Therapeutics Enter into Licensing and Collaboration Agreement for NeuroSTAT in Traumatic Brain Injury	Nov. 14	CI
Abliva AB Achieves Important Milestone in the Ongoing FALCON Study	23-10-11	CI
Abliva Rises 28% on US FDA Fast Track Designation for Mitochondrial Disease Drug Candidate	23-09-04	MT
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-18	CI
Abliva AB Announces First Patient Dosed in the Falcon Study	23-06-28	CI
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-23	CI
Abliva AB Announces Resignation of Edwin Moses as Director	23-05-04	CI
Abliva Up 15% on US FDA's Orphan Designation for Mitochondrial Disease Treatment Candidate	23-04-17	MT
Abliva AB Elects Edwin Moses as New Board Member	23-03-08	CI
Abliva AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-02-24	CI
Abliva AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-24	CI
Certain Shares of Abliva AB are subject to a Lock-Up Agreement Ending on 28-DEC-2022.	22-12-27	CI
Abliva Starts Mid-stage Study Of Rare Metabolical Disease Drug	22-12-06	MT
Abliva AB Initiates the Global Falcon Study with Lead Candidate KL1333	22-12-06	CI
Abliva AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-22	CI
Abliva AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-19	CI
Transcript : Abliva AB - Special Call	22-06-01
Abliva AB Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-31	CI
Abliva AB Auditor Raises 'Going Concern' Doubt	22-04-28	CI
Abliva AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021	22-02-22	CI
Abliva AB Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-22	CI

Chart Abliva AB

Duration

Period

More charts

Company Profile

Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-05-20 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ABLIVA AB	-21.38%	23.02M
VERTEX PHARMACEUTICALS INCORPORATED	+9.58%	115B
REGENERON PHARMACEUTICALS, INC.	+12.41%	106B
ARGENX SE	-2.59%	21.96B
BIONTECH SE	-12.38%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-3.35%	18.08B
WUXI APPTEC CO., LTD.	-38.57%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.51%	14.32B
SAREPTA THERAPEUTICS, INC.	+35.67%	12.42B

Bio Therapeutic Drugs

Abliva AB

Equities

ABLI

SE0002575340

Biotechnology & Medical Research

NeuroVive Pharmaceutical AB Elects Magnus Persson as New Board Member

Latest news about Abliva AB

Chart Abliva AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs